Communiqués Aptahem AB

Actions

APTA

SE0022447173

Recherche biotechnologique et médicale

Cours en clôture NORDIC GROWTH MARKET 28/08/2026			Varia. 5j.	Varia. 1 janv.
0,5200 ^SEK	0,00%		+4,00%	-54,59%

08:57	Aptahem intensifie ses efforts de partenariat autour d'Apta-1	FW
27/08	Aptahem AB (publ) publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

25/08	Aptahem: Aptahem enters commercial partnership agreement with Jarlen Capital for outlicensing	PU
25/08	Aptahem enters commercial partnership agreement with Jarlen Capital for outlicensing	AQ
22/06	Aptahem: Newsletter June 2026	PU
22/06	Newsletter June 2026	AQ
17/06	Aptahem: Aptahem Improves Quality and Manufacturing Efficiency in a New Apta-1 Test Batch	PU
17/06	Aptahem Improves Quality and Manufacturing Efficiency in a New Apta-1 Test Batch	AQ
05/06	Aptahem: Aptahem to Participate at IOPC 2026 in Athens	PU
05/06	Aptahem to Participate at IOPC 2026 in Athens	AQ
11/05	Aptahem: Newsletter May 2026	PU
11/05	Newsletter May 2026	AQ
19/12	Aptahem: Newsletter December 2025	PU
19/12	Newsletter December 2025	AQ
05/12	Aptahem receives patent protection in China for patent family 2	AQ
30/10/25	Aptahem: Aptahem’s webinar "Strategic Direction and Planned US Listing" now available	PU
30/10/25	Aptahem : webinar ”Strategic Direction and Planned US Listing” now available	PU
30/10/25	Aptahem's webinar "Strategic Direction and Planned US Listing" now available	AQ
22/10/25	Aptahem: Aptahem Announces English-Language Webinar on Strategic Direction and Planned U.S. Listing	PU
22/10/25	Aptahem Announces English-Language Webinar on Strategic Direction and Planned U.S. Listing	AQ
21/10/25	Aptahem: Newsletter October 2025	PU
21/10/25	Newsletter October 2025	AQ
15/10/25	VD:s tankar om AMR och sepsis	PU
15/10/25	Aptahem : CEO’s thoughts on AMR and sepsis	PU
13/10/25	Aptahem : Mikael Lindstam shares his reflections from BIO Japan	PU
25/09/25	Aptahem: Aptahem moves forward with focus on U.S. listing strategy, regulatory progress, and partner engagement following outcome of rights issue	PU
25/09/25	Aptahem moves forward with focus on U.S. listing strategy, regulatory progress, and partner engagement following outcome of rights issue	AQ